Published in Drug Alcohol Depend on September 19, 2008
Opioid Dependence Treatment Therapies in Pregnancy | NCT03098407
Cost evaluation of evidence-based treatments. Addict Sci Clin Pract (2010) 1.42
Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann Intern Med (2008) 1.30
Cost-effectiveness of computer-assisted training in cognitive-behavioral therapy as an adjunct to standard care for addiction. Drug Alcohol Depend (2010) 1.10
Application of multivariate probabilistic (Bayesian) networks to substance use disorder risk stratification and cost estimation. Perspect Health Inf Manag (2009) 1.09
Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat (2014) 1.05
Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med (2012) 0.95
Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict (2010) 0.92
Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone. J Gen Intern Med (2010) 0.90
Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence. Neuropsychiatr Dis Treat (2014) 0.90
Costs of care for persons with opioid dependence in commercial integrated health systems. Addict Sci Clin Pract (2014) 0.89
Physicians' attitudes towards office-based delivery of methadone maintenance therapy: results from a cross-sectional survey of Nova Scotia primary-care physicians. Harm Reduct J (2012) 0.85
The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. J Acquir Immune Defic Syndr (2011) 0.81
Treatment of prescription opioid disorders in Canada: looking at the 'other epidemic'? Subst Abuse Treat Prev Policy (2016) 0.80
Buprenorphine versus methadone use in opiate detoxification, are there other factors that should be considered? Br J Gen Pract (2012) 0.79
A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders. Ann N Y Acad Sci (2014) 0.78
Factors associated with buprenorphine versus methadone use in pregnancy. Subst Abus (2016) 0.78
Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals. Subst Abuse Rehabil (2016) 0.76
Economic analysis of a multi-site prevention program: assessment of program costs and characterizing site-level variability. Prev Sci (2013) 0.76
The cost of providing methadone maintenance treatment in Ontario, Canada. Am J Drug Alcohol Abuse (2012) 0.76
The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat (1992) 29.45
Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA (1998) 5.20
A new measure of substance abuse treatment. Initial studies of the treatment services review. J Nerv Ment Dis (1992) 4.64
The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction (2001) 3.87
Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med (2006) 3.64
An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat (2005) 3.46
The economic costs of heroin addiction in the United States. Drug Alcohol Depend (2001) 2.90
Buprenorphine retention in primary care. J Gen Intern Med (2005) 2.57
What do we get for our money? Cost-effectiveness of adding contingency management. Addiction (2007) 2.51
Methadone maintenance in primary care: a randomized controlled trial. JAMA (2001) 2.35
Cost-effectiveness of prize-based contingency management in methadone maintenance treatment programs. Addiction (2007) 2.11
Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med (2007) 1.84
The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med (2007) 1.83
HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health (2000) 1.74
The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend (2005) 1.72
Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat (2004) 1.70
Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend (2003) 1.68
New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med (2002) 1.62
Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug Alcohol Depend (2006) 1.60
DATStats: results from 85 studies using the Drug Abuse Treatment Cost Analysis Program. J Subst Abuse Treat (2003) 1.58
Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain (2006) 1.56
Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict (2008) 1.45
Cost-benefit analysis of drug treatment services: review of the literature* J Ment Health Policy Econ (2000) 1.44
The cost-effectiveness of methadone maintenance. Mt Sinai J Med (2000) 1.44
The cost-effectiveness of methadone maintenance as a health care intervention. Addiction (1999) 1.36
Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. Am J Psychiatry (1999) 1.34
Service-level costing of drug abuse treatment. J Subst Abuse Treat (1998) 1.33
A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics (2005) 1.15
Office-based practice and opioid-use disorders. N Engl J Med (2003) 1.13
Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend (2001) 1.06
Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis (2006) 1.03
Pharmaco-economics of community maintenance for opiate dependence: a review of evidence and methodology. Drug Alcohol Depend (2006) 0.94
The cost and cost-effectiveness of an enhanced intervention for people with substance abuse problems at risk for HIV. Health Serv Res (2001) 0.92
The costs of crime and the benefits of drug abuse treatment: a cost-benefit analysis using TOPS data. NIDA Res Monogr (1988) 0.89
Financing and cost of standard and enhanced methadone treatment. J Subst Abuse Treat (1995) 0.89
Buprenorphine: an alternative to methadone. Med Lett Drugs Ther (2003) 0.82
Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain (2009) 9.36
Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med (2007) 5.68
Management of drug and alcohol withdrawal. N Engl J Med (2003) 4.12
Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med (2006) 3.64
Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry (2004) 3.26
Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med (2002) 3.20
Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry (2011) 3.15
Brief intervention for hazardous and harmful drinkers in the emergency department. Ann Emerg Med (2008) 3.12
Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend (2007) 2.99
Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med (2002) 2.74
The time course and significance of cannabis withdrawal. J Abnorm Psychol (2003) 2.70
A brief intervention reduces hazardous and harmful drinking in emergency department patients. Ann Emerg Med (2012) 2.68
Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis (2012) 2.45
Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med (2007) 2.38
Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med (2007) 2.38
Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis (2014) 2.24
Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol (2006) 2.15
Gender and non-medical use of prescription opioids: results from a national US survey. Addiction (2007) 2.15
An evidence-based guide to writing grant proposals for clinical research. Ann Intern Med (2005) 2.13
Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction (2005) 2.05
Methods of detoxification and their role in treating patients with opioid dependence. JAMA (2005) 2.02
Paying for performance: the power of incentives over habits. Health Econ (2008) 1.98
The prevalence and impact of alcohol problems in major depression: a systematic review. Am J Med (2005) 1.98
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr (2011) 1.97
Smoking status as a clinical indicator for alcohol misuse in US adults. Arch Intern Med (2007) 1.92
Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat (2008) 1.89
A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med (2013) 1.77
Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse (2002) 1.76
Spousal concordance in health behavior change. Health Serv Res (2008) 1.75
Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med (2003) 1.74
Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry (2007) 1.73
Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend (2006) 1.73
The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend (2005) 1.72
Effects of a cost-sharing exemption on use of preventive services at one large employer. Health Aff (Millwood) (2006) 1.69
Terminal decontamination of patient rooms using an automated mobile UV light unit. Infect Control Hosp Epidemiol (2011) 1.67
The impact of tobacco expenditure on household consumption patterns in rural China. Soc Sci Med (2005) 1.66
Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Soc Sci Med (2002) 1.66
A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis (2006) 1.62
New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med (2002) 1.62
Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug Alcohol Depend (2006) 1.60
Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr (2011) 1.52
Gambling: an addictive behavior with health and primary care implications. J Gen Intern Med (2002) 1.52
The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med (2010) 1.51
Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population. J Clin Psychiatry (2015) 1.51
The effect of involuntary job loss on smoking intensity and relapse. Addiction (2005) 1.49
Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI. Health Serv Res (2002) 1.48
Delay discounting in current and former marijuana-dependent individuals. Exp Clin Psychopharmacol (2010) 1.48
Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med (2008) 1.45
Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict (2008) 1.45
Federal plan for prescriber education on opioids misses opportunities. Ann Intern Med (2012) 1.45
Women and opioid dependence treatment: office-based versus opioid treatment program-based care? Subst Abus (2007) 1.42
Alcohol problems and health care services use in human immunodeficiency virus (HIV)-infected and HIV-uninfected veterans. Med Care (2006) 1.41
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat (2007) 1.38
Food insecurity is associated with poor virologic response among HIV-infected patients receiving antiretroviral medications. J Gen Intern Med (2011) 1.37
Increased hospital and emergency department utilization by individuals with recent criminal justice involvement: results of a national survey. J Gen Intern Med (2014) 1.35
Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug Alcohol Depend (2013) 1.33
Relations among psychopathology, substance use, and physical pain experiences in methadone-maintained patients. J Clin Psychiatry (2009) 1.33
Development and implementation of an emergency practitioner-performed brief intervention for hazardous and harmful drinkers in the emergency department. Acad Emerg Med (2005) 1.31
The next therapeutic challenge in HIV: polypharmacy. Drugs Aging (2013) 1.30
Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann Intern Med (2008) 1.30
The cost-effectiveness of four treatments for marijuana dependence. Addiction (2007) 1.29
Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. J Gen Intern Med (2007) 1.27
Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Ann Intern Med (2010) 1.27
Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis (2005) 1.24
Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US Veteran cohort. Drug Alcohol Depend (2010) 1.23
A research agenda for enhancing appropriate opioid prescribing in primary care. J Gen Intern Med (2013) 1.23
The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med (2006) 1.21
Pain and substance-related pain-reduction behaviors among opioid dependent individuals seeking methadone maintenance treatment. Am J Addict (2009) 1.19
Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis (2006) 1.19
Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci (2008) 1.18
Economic costs of influenza-related work absenteeism. Value Health (2003) 1.18